These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20409643)

  • 1. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers.
    Powell C; Mikropoulos C; Kaye SB; Nutting CM; Bhide SA; Newbold K; Harrington KJ
    Cancer Treat Rev; 2010 Nov; 36(7):566-75. PubMed ID: 20409643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase.
    Brock WA; Milas L; Bergh S; Lo R; Szabó C; Mason KA
    Cancer Lett; 2004 Mar; 205(2):155-60. PubMed ID: 15036647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Drew Y; Calvert H
    Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.
    Pogrebniak A; Schemainda I; Pelka-Fleischer R; Nüssler V; Hasmann M
    Eur J Med Res; 2003 Oct; 8(10):438-50. PubMed ID: 14594650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
    Smith LM; Willmore E; Austin CA; Curtin NJ
    Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
    Masutani M; Nakagama H; Sugimura T
    Cell Mol Life Sci; 2005 Apr; 62(7-8):769-83. PubMed ID: 15868402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.
    Bryant HE; Helleday T
    Biochem Soc Trans; 2004 Dec; 32(Pt 6):959-61. PubMed ID: 15506935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of the radiation-sensitive phenotype of hamster irs1 and irs2 strains selected for resistance to 3-aminobenzamide.
    Ganesh A; Phillips E; Thacker J; Meuth M
    Int J Radiat Biol; 2001 May; 77(5):609-16. PubMed ID: 11382339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical development of PARP inhibitors].
    Toyoda M; Minami H
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):519-24. PubMed ID: 22504675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
    Pernin V; Mégnin-Chanet F; Pennaneach V; Fourquet A; Kirova Y; Hall J
    Cancer Radiother; 2014 Dec; 18(8):790-8; quiz 799-802. PubMed ID: 25441760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
    Menear KA; Adcock C; Boulter R; Cockcroft XL; Copsey L; Cranston A; Dillon KJ; Drzewiecki J; Garman S; Gomez S; Javaid H; Kerrigan F; Knights C; Lau A; Loh VM; Matthews IT; Moore S; O'Connor MJ; Smith GC; Martin NM
    J Med Chem; 2008 Oct; 51(20):6581-91. PubMed ID: 18800822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427.
    Khan K; Araki K; Wang D; Li G; Li X; Zhang J; Xu W; Hoover RK; Lauter S; O'Malley B; Lapidus RG; Li D
    Head Neck; 2010 Mar; 32(3):381-91. PubMed ID: 19672867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea and trimidox enhance the radiation effect in human pancreatic adenocarcinoma cells.
    Leyden D; Ahmed N; Hassan HT
    Anticancer Res; 2000; 20(1A):133-8. PubMed ID: 10769645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
    Eltze T; Boer R; Wagner T; Weinbrenner S; McDonald MC; Thiemermann C; Bürkle A; Klein T
    Mol Pharmacol; 2008 Dec; 74(6):1587-98. PubMed ID: 18809672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.